Advertisement
Research Article

Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood

  • Robert De Rose,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Caroline S. Fernandez,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Miranda Z. Smith,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • C. Jane Batten,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Sheilajen Alcântara,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Vivienne Peut,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Erik Rollman,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Liyen Loh,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Rosemarie D. Mason,

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Kim Wilson,

    Affiliation: National Serology Reference Laboratory, Fitzroy, Victoria, Australia

    X
  • Matthew G. Law,

    Affiliation: National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia

    X
  • Amanda J. Handley,

    Affiliations: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia, Opal Therapeutics Pty Ltd, Melbourne, Victoria, Australia

    Medicines Development Ltd, Melbourne, Victoria, Australia

    X
  • Stephen J. Kent mail

    skent@unimelb.edu.au

    Affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia

    X
  • Published: May 02, 2008
  • DOI: 10.1371/journal.ppat.1000055

About the Authors

Robert De Rose, Caroline S. Fernandez, Miranda Z. Smith, C. Jane Batten, Sheilajen Alcântara, Vivienne Peut, Erik Rollman, Liyen Loh, Rosemarie D. Mason, Amanda J. Handley, Stephen J. Kent
Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
Kim Wilson
National Serology Reference Laboratory, Fitzroy, Victoria, Australia
Matthew G. Law
National Centre for HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, New South Wales, Australia
Amanda J. Handley
Opal Therapeutics Pty Ltd, Melbourne, Victoria, Australia

Corresponding Author

Email: skent@unimelb.edu.au

Competing Interests

SJK spun out a venture capital–backed biotechnology start-up company, OPAL Therapeutics Pty Ltd, to pursue this technology towards clinical trials. SJK, CJB and the University of Melbourne hold shares in this company. AJH has been an employee of OPAL Therapeutics.

Author Contributions

Conceived and designed the experiments: SK. Performed the experiments: RD CF MS CB SA VP ER LL RM KW AH SK. Analyzed the data: ML SK. Wrote the paper: SK. Performed the statistical analyses: ML. Audited the study: AH.